Impact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines

被引:0
|
作者
Fernandez-Ciriza, Leire [1 ]
del Pozo, Jose Luis [1 ,2 ,3 ]
Betanzos, Nazaret [1 ]
Gonzalez, Alvaro [2 ,4 ]
Fernandez-Montero, Alejandro [2 ,5 ]
Carmona-Torre, Francisco [2 ,3 ]
Vidaurreta, Marta [1 ,2 ,4 ]
Carlos, Silvia [2 ,6 ]
Reina, Gabriel [1 ,2 ]
机构
[1] Clin Univ Navarra, Dept Microbiol, Pamplona 31008, Spain
[2] Navarra Inst Hlth Res IdiSNA, Pamplona 31008, Spain
[3] Clin Univ Navarra, Infect Dis Div, Pamplona 31008, Spain
[4] Clin Univ Navarra, Dept Biochem, Pamplona 31008, Spain
[5] Univ Navarra, Dept Occupat Med, Pamplona 31008, Spain
[6] Univ Navarra, Dept Prevent Med & Publ Hlth, Pamplona 31008, Spain
关键词
mRNA vaccine; Omicron; reinfection; cellular immunity; humoral immunity; fourth dose; COVID-19;
D O I
10.3390/vaccines12121408
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background/Objectives: The emergence of the Omicron variant has complicated COVID-19 control and prompted vaccine updates. Recent studies have shown that a fourth dose significantly protects against infection and severe disease, though long-term immunity data remain limited. This study aimed to assess Anti-S-RBD antibodies and interferon-gamma levels in healthcare workers 12 months after receiving bivalent Original/Omicron BA.4-5 fourth SARS-CoV-2 vaccine. Methods: In this prospective cohort study, 549 healthcare workers were categorized by the initial vaccination schedule, with 229 individuals having received the fourth SARS-CoV-2 vaccine dose. Blood samples were collected from all participants 12 months post-vaccination. Results: Significant differences in Anti-S-RBD antibody levels were observed between those receiving a fourth dose and those who did not, while no differences were seen in interferon-gamma levels. After 12 months, there were no significant differences in humoral and cellular immunity response between volunteers primoinfected or reinfected across different periods by the Omicron variant. A multivariable analysis revealed an association between high antibody levels (>6000 U/mL) and interferon-gamma levels (OR: 3.13; 95% CI: 1.3-7.7; p < 0.05). Regarding primary vaccine schedules, participants vaccinated with ChAdOx1 (a single or double dose) had notably lower antibody levels compared to those who received mRNA-based vaccines. Additionally, the study shows a higher frequency of multiple infections among those with a single-dose ChAdOx1 primary schedule (OR: 6.24; 95% CI: 1.25-31.15; p < 0.01). Conclusions: Overall, mRNA-based vaccines exhibited stronger long-term immunogenicity. Repeated exposure to the Omicron variant seems to mitigate immune imprinting from the wild-type SARS-CoV-2. An association was observed between high antibody levels and a strong cellular response, although the correlation was not linear.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Humoral and cellular immune responses to repeated SARS-CoV-2 infection and vaccination in an individual living with HIV
    Simsek, Agit
    Bessen, Clara
    Meister, Toni L.
    Urlaub, Doris
    Skaletz-Rorowski, Adriane
    Brockmeyer, Norbert H.
    Overheu, Oliver
    Reinacher-Schick, Anke
    Faissner, Simon
    Watzl, Carsten
    Pfaender, Stephanie
    Schmitz, Ingo
    Potthoff, Anja
    Plaza-Sirvent, Carlos
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (07) : E825 - E827
  • [32] Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants
    Kim, Se Eun
    Park, So Hee
    Park, Woo-Jung
    Kim, Gayeong
    Kim, Seo Yeon
    Won, Hyeran
    Hwang, Yun-Ho
    Lim, Heeji
    Kim, Hyeon Guk
    Kim, You-Jin
    Kim, Dokeun
    Lee, Jung-Ah
    PLOS ONE, 2023, 18 (12):
  • [33] SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
    Joyce, M.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2021, 77 : A163 - A163
  • [34] SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
    Joyce, M. Gordon
    Chen, Wei-Hung
    Sankhala, Rajeshwer S.
    Hajduczki, Agnes
    Thomas, Paul, V
    Choe, Misook
    Martinez, Elizabeth J.
    Chang, William C.
    Peterson, Caroline E.
    Morrison, Elaine B.
    Smith, Clayton
    Chen, Rita E.
    Ahmed, Aslaa
    Wieczorek, Lindsay
    Anderson, Alexander
    Case, James Brett
    Li, Yifan
    Oertel, Therese
    Rosado, Lorean
    Ganesh, Akshaya
    Whalen, Connor
    Carmen, Joshua M.
    Mendez-Rivera, Letzibeth
    Karch, Christopher P.
    Gohain, Neelakshi
    Villar, Zuzana
    McCurdy, David
    Beck, Zoltan
    Kim, Jiae
    Shrivastava, Shikha
    Jobe, Ousman
    Dussupt, Vincent
    Molnar, Sebastian
    Tran, Ursula
    Kannadka, Chandrika B.
    Soman, Sandrine
    Kuklis, Caitlin
    Zemil, Michelle
    Khanh, Htet
    Wu, Weimin
    Cole, Matthew A.
    Duso, Debra K.
    Kummer, Larry W.
    Lang, Tricia J.
    Muncil, Shania E.
    Currier, Jeffrey R.
    Krebs, Shelly J.
    Polonis, Victoria R.
    Rajan, Saravanan
    McTamney, Patrick M.
    CELL REPORTS, 2021, 37 (12):
  • [35] Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses
    Buscot, Matthieu
    Cremoni, Marion
    Graca, Daisy
    Brglez, Vesna
    Courjon, Johan
    Allouche, Jonathan
    Teisseyre, Maxime
    Boyer, Laurent
    Barriere, Jerome
    Chamorey, Emmanuel
    Carles, Michel
    Seitz-Polski, Barbara
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [36] Impact of SARS-CoV-2 vaccines on the nervous system
    Scorza, Fulvio Alexandre
    Finsterer, Josef
    CLINICAL IMAGING, 2022, 82 : 13 - 14
  • [37] Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
    Petrone, Linda
    Tortorella, Carla
    Aiello, Alessandra
    Farroni, Chiara
    Ruggieri, Serena
    Castilletti, Concetta
    Meschi, Silvia
    Cuzzi, Gilda
    Vanini, Valentina
    Palmieri, Fabrizio
    Prosperini, Luca
    Haggiag, Shalom
    Galgani, Simona
    Grifoni, Alba
    Sette, Alessandro
    Gasperini, Claudio
    Nicastri, Emanuele
    Goletti, Delia
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [38] Impact of SARS-CoV-2 variants on mRNA vaccines
    Venkatesan, Priya
    LANCET MICROBE, 2021, 2 (09): : E428 - E428
  • [39] SARS-CoV-2 Vaccines
    Creech, C. Buddy
    Walker, Shannon C.
    Samuels, Robert J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (13): : 1318 - 1320
  • [40] Impaired Humoral Immunogenicity of SARS-CoV-2 Vaccination in Patients With Rheumatoid Arthritis
    Le Moine, Camille
    Soyfoo, Muhammad Shahnawaz
    Mekkaoui, Leila
    Dahma, Hafid
    Tant, Laure
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 855 - 858